Trials / Completed
CompletedNCT00504608
A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- Female
- Age
- 21 Years – 37 Years
- Healthy volunteers
- —
Summary
The primary objective of the study was to provide further clinical and statistical evidence of the efficacy of r-hLIF, in comparison with placebo, administered during the luteal phase after IVF and ET for improving embryo implantation in infertile women with a history of at least 2 implantation failures following transfer of fresh embryos. The secondary objective of the study was to assess the safety profile of r-hLIF in the proposed indication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2004-04-01
- Completion
- 2004-04-01
- First posted
- 2007-07-20
- Last updated
- 2017-01-04
Source: ClinicalTrials.gov record NCT00504608. Inclusion in this directory is not an endorsement.